Cwm LLC Has $43,000 Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)

Cwm LLC boosted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 216.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,011 shares of the company’s stock after acquiring an additional 1,376 shares during the quarter. Cwm LLC’s holdings in Denali Therapeutics were worth $43,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in DNLI. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Denali Therapeutics by 11.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,679 shares of the company’s stock worth $427,000 after purchasing an additional 2,124 shares in the last quarter. TD Asset Management Inc boosted its stake in shares of Denali Therapeutics by 59.9% during the 3rd quarter. TD Asset Management Inc now owns 135,000 shares of the company’s stock worth $2,785,000 after acquiring an additional 50,578 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Denali Therapeutics by 49.1% during the 3rd quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock valued at $44,000 after acquiring an additional 707 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Denali Therapeutics by 96.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,526 shares of the company’s stock valued at $73,000 after acquiring an additional 1,732 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in Denali Therapeutics by 4.8% in the 3rd quarter. Teacher Retirement System of Texas now owns 31,102 shares of the company’s stock worth $642,000 after purchasing an additional 1,437 shares during the last quarter. 92.92% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on DNLI shares. HC Wainwright restated a “buy” rating and issued a $95.00 price objective on shares of Denali Therapeutics in a research note on Wednesday. Stifel Nicolaus decreased their target price on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating for the company in a research note on Wednesday. The Goldman Sachs Group dropped their price target on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Wedbush reduced their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, UBS Group cut their target price on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, April 9th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $40.22.

Denali Therapeutics Price Performance

Shares of DNLI stock opened at $18.67 on Friday. The stock has a market cap of $2.66 billion, a P/E ratio of -17.29 and a beta of 1.39. The stock has a fifty day moving average price of $18.77 and a 200 day moving average price of $18.84. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.31.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.01. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same quarter last year, the company posted ($0.80) EPS. Equities research analysts anticipate that Denali Therapeutics Inc. will post -2.61 EPS for the current year.

Insider Activity

In related news, Director Steve E. Krognes sold 92,500 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $20.50, for a total value of $1,896,250.00. Following the sale, the director now owns 47,341 shares of the company’s stock, valued at approximately $970,490.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Denali Therapeutics news, Director Steve E. Krognes sold 92,500 shares of Denali Therapeutics stock in a transaction on Monday, April 1st. The stock was sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the completion of the transaction, the director now directly owns 47,341 shares of the company’s stock, valued at $970,490.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 1,666 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $18.37, for a total transaction of $30,604.42. Following the completion of the sale, the director now directly owns 121,375 shares in the company, valued at approximately $2,229,658.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 110,955 shares of company stock worth $2,218,802. Company insiders own 7.90% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.